Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.
Crystalys Therapeutics’ gout drug, dotinurad, inhibits a known and validated target for treating the chronic disorder, but in a way that could be safer than other drugs. The oral small molecule was discovered and developed in Japan, where it is approved and has a safety record spanning more than 1 million gout patients.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.